Operator-led advisory for growth-stage SaaS businesses serving Life Sciences, Digital Health and AI markets. Sprint diagnostics, fractional CGO engagements, and non-executive director seats.
Typical outcomes: revenue and operating rhythm installed, ISO 9001, ISO 27001 and SOC 2 readiness that unlocks enterprise and regulated deals, commercial clarity where AI is reshaping how customers buy, and partner channels that carry real numbers.
Boards do not need more material. They need a catalyst. The one input that dissolves the noise and leaves the room with a decision the company can act on. Every Ortent engagement is built around that single act of clarification: drop in, dissolve the complexity, leave the call.
"Andrew is one of the few SaaS leaders I've worked with who genuinely understands how to build commercial relationships at the intersection of life sciences and software. He thinks like a partner, not a vendor, which is exactly what makes the work move."
"Andrew's one of those rare breeds who really understands technology, but also has the listening and strategic skills to read customers and markets. Smart guy."
"Andrew approaches AI-related commercial, legal, and privacy risks with a deep understanding and the strategic insight of a board member. He excels at balancing the potential for revenue growth and competitive advantage with the necessary regulatory compliance and risk management, all while communicating these complexities with ease."
"Andrew is one of the sharpest commercial operators I've worked with, and a charismatic leader people love to work for. He sees the GTM motion and the customer simultaneously, and he builds partner ecosystems that drive pipeline rather than just logo slides."
"Zifo and Sapio have collaborated closely for several years, working together to ensure seamless integration of the Sapio Platform with our Lab Data Automation Solution. By combining our expertise in scientific informatics services with Sapio's lab informatics solutions, we can provide our customers with a world-class approach to lab automation and further the adoption of AI in biotech and pharma."
"The partner program Andrew built at Sapio set a new bar for what life sciences software ecosystems can look like. He made it easy for global services partners like Cognizant to invest, deliver, and grow alongside the platform, which is rarer than it should be."
"Working with Andrew on the Sapio and Elsevier collaboration showed me what AI ecosystem thinking looks like in practice. He moves the conversation past 'how do we integrate?' and into 'how do our two products make each other more valuable?'. That design instinct is what separates a partnership that compounds from a logo on a slide."
Three clearly packaged engagements, each with a defined shape, fee and outcome so founders and boards can buy quickly. Most engagements start with a Sprint Diagnostic. For a worked example of the kind of artefact one produces, explore the interactive target operating model.
Four to eight weeks, fixed scope, fixed fee. One commercial question answered cleanly: pipeline reset, operating rhythm, AI-era go-to-market decisions, partner strategy or alliance design. You walk away with a defensible answer and a plan the leadership team can execute on Monday.
Embedded commercial and operating leader. Revenue, partnerships and alliances on one side; revenue operations, forecast discipline, partner operations and ISO 9001, ISO 27001 and SOC 2 readiness on the other. Typically 2–4 days a month for 6–12 months.
Board seat with standard NED terms. Quarterly board plus chair and CEO 1:1s and light committee work. Best suited to growth-stage B2B SaaS serving life sciences, digital health and AI-native markets, where commercial clarity, operating maturity and partner-led growth are material to value.
Options, trade-offs, decisions. We turn noisy pipelines and strategy decks into a clear operating course the whole leadership team can execute.
Deep context in enterprise SaaS selling into life sciences, digital health, informatics and AI-native markets. We understand how AI is reshaping the buy decision for regulated scientific and healthcare markets.
Revenue operations, forecast hygiene, partner operations, and ISO 9001, ISO 27001 and SOC 2 readiness run as commercial investments, not compliance chores.
Most partner programmes are theatre. Ortent designs and runs alliances that carry real revenue, with named partners, joint plays and shared numbers.
Four exits of experience compressed into a playbook. We help leadership teams build the commercial architecture that makes a company buyable on its own terms.
Every engagement is built around a written artefact the board can act on. If we cannot define the deliverable in one line, the engagement is not yet ready to start.
Three practical guides for PE operating partners, chairs and CEOs deciding how to install commercial leadership, partner-led growth, or independent governance in growth-stage SaaS businesses serving life sciences and digital health markets.
What the role actually owns, when to hire one, what it costs in the UK in 2026, and the six KPIs that prove the work.
The four partner archetypes, the AI co-growth model, and how to design economics that compound rather than transact.
Governance, challenge, and the named-introductions test most founders underweight when they hire their first NED.
Four prior exits taught me that companies are rarely undone by strategy. They are undone by how revenue, operating discipline and partnerships fit together under pressure.
Ortent is the advisory practice of Andrew Wyatt, formerly a commercial leader at Sapio Sciences, Lumeon, Apertio and Clearswift. AI is reshaping how customers buy, and the operators who can name what is genuinely new from what is just noise are now the ones boards reach for.
Ortent is where I bring that work to founders, boards and investors who need clear commercial judgment at a pivotal moment. Particularly enterprise SaaS businesses selling into life sciences, digital health and AI-native markets, where regulated and scientific customers are the next growth unlock.
A short note every few weeks on commercial clarity, AI-era go-to-market, and board discipline in growth-stage companies. No marketing, no cadence theatre.
Delivered via Substack. You can unsubscribe any time. See our privacy notice.
If you have a board seat, a fractional mandate or a commercial reset coming up in the next 90 days, email directly. We'll book 30 minutes to see whether Ortent is the right fit.
Send a note →